Radioligand therapy for primary brain tumors: a PRISMA-based systematic review of meningiomas and gliomas
Despite the heterogeneity of the studies, RLT emerges as a promising therapeutic strategy in neuro-oncology. Its theranostic paradigm offers a distinctive advantage, enabling patient selection, treatment personalization, and response monitoring. The development of potentially novel radiopharmaceuticals and the conduct of well-designed multicenter trials with standardized response criteria are needed to further increase the impact and clinical translation of RLT in neuro-oncology.
Authors
- Irene Marini (ORCID: https://orcid.org/0009-0002-6186-688X)
- Donatella Arpa
- Valentina Di Iorio (ORCID: https://orcid.org/0000-0002-5380-6185)
- Virginia Rossetti (ORCID: https://orcid.org/0000-0001-6052-8729)
- Silvia Nicolini (ORCID: https://orcid.org/0000-0002-3960-7737)
- Anna Sarnelli (ORCID: https://orcid.org/0000-0001-5986-3845)
- Maddalena Sansovini (ORCID: https://orcid.org/0000-0002-7699-262X)
- Federica Matteucci (ORCID: https://orcid.org/0000-0001-7455-6253)
- Lorenzo Fantini
- Ilaria Bronico
- Lorena Gurrieri (ORCID: https://orcid.org/0000-0001-8935-8794)
- Monica Celli (ORCID: https://orcid.org/0000-0002-0338-800X)
- Alessandro Rossi (ORCID: https://orcid.org/0000-0002-0479-9732)
- Paola Caroli
- Ilaria Grassi
- Nada Riva
Institutions
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2026-01-23
- DOI
- https://doi.org/10.3389/fmed.2025.1728797
- Primary Topic
- Meningioma and schwannoma management
- Type
- article
- Field-Weighted Citation Impact
- 0.00